Rojas Kristin E, Butler Elizabeth, Gutierrez Julie, Kwait Rebecca, Laprise Jessica, Wilbur Jennifer Scalia, Spinette Sarah, Raker Christina A, Robison Katina, Legare Robert, Gass Jennifer, Stuckey Ashley
Brooklyn Breast Program, Maimonides Medical Center, Brooklyn NY, USA.
Saint Luke's Hospital of Kansas City, Kansas City, MO, USA.
Gland Surg. 2019 Jun;8(3):249-257. doi: 10.21037/gs.2019.04.08.
We have previously shown that breast cancer surgery affects breast specific sensuality, and that women who undergo mastectomy may have worse sexual function outcomes than those who undergo lumpectomy. It is less clear if patients who undergo prophylactic mastectomy are equally as affected as those with a cancer diagnosis. We sought to compare sexual function outcomes and their relationship to depression and anxiety between BRCA mutation carriers (mBRCA) with and without cancer in order to guide surgical counseling and improve survivorship outcomes.
A confidential, cross-sectional survey was distributed electronically to mBRCA at least 18 years of age. The survey included investigator-generated questions, the Female Sexual Function Index (FSFI), and the Hospital Anxiety and Depression Scale (HADS) surveys. Responses were analyzed in total and divided into two subgroups: those with and without breast cancer.
Sixty-three mBRCA responded (37%) of 170 email addresses were identified, and 77% were postmenopausal. Although more than half of all mBRCA reported that the role of the breast in intimacy was important, most patients without cancer and all of those with cancer experienced an impressive decline in certain breast-specific sensuality parameters postoperatively. Among those without cancer, anxiety scores were not different between those choosing prophylactic mastectomy and high-risk screening (HRS). Sexual function as measured by the FSFI was negatively correlated with depression and anxiety in mBRCA. FSFI scores were not significantly different between those with and without cancer. However, the median FSFI of mBRCA with cancer, those undergoing HRS, and those who underwent prophylactic mastectomy indicated sexual dysfunction.
As the availability of genetic testing increases, more women are found to harbor BRCA mutations and must choose between HRS and prophylactic surgery. Women with BRCA mutations, both with and without breast cancer, are susceptible to derangements in sexual function during the course of both screening or treatment, and this appears to be negatively correlated to depression and anxiety.
我们之前已经表明,乳腺癌手术会影响乳房特定的性感,并且接受乳房切除术的女性可能比接受肿块切除术的女性性功能结局更差。接受预防性乳房切除术的患者是否与患有癌症诊断的患者受到同样的影响尚不清楚。我们试图比较携带BRCA突变(mBRCA)且有或无癌症的患者的性功能结局及其与抑郁和焦虑的关系,以指导手术咨询并改善生存结局。
向至少18岁的mBRCA以电子方式分发了一份保密的横断面调查问卷。该调查包括研究人员提出的问题、女性性功能指数(FSFI)和医院焦虑抑郁量表(HADS)调查。对回答进行了总体分析,并分为两个亚组:有和没有乳腺癌的患者。
170个电子邮件地址中有63个mBRCA做出了回应(37%),77%为绝经后女性。尽管超过一半的所有mBRCA报告乳房在亲密关系中的作用很重要,但大多数无癌症患者和所有癌症患者术后在某些乳房特定性感参数方面都出现了显著下降。在无癌症患者中,选择预防性乳房切除术和高危筛查(HRS)的患者焦虑评分没有差异。通过FSFI测量的性功能与mBRCA中的抑郁和焦虑呈负相关。有和没有癌症的患者之间FSFI评分没有显著差异。然而,患有癌症的mBRCA、接受HRS的患者以及接受预防性乳房切除术的患者的FSFI中位数表明存在性功能障碍。
随着基因检测的可及性增加,发现更多女性携带BRCA突变,并且必须在HRS和预防性手术之间做出选择。携带BRCA突变的女性,无论有无乳腺癌,在筛查或治疗过程中都易出现性功能紊乱,并且这似乎与抑郁和焦虑呈负相关。